Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 9/20 | 0.47 |
| ▸ | SIK1 | P57059 | 2/20 | 0.47 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.47 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762150 | 0.90 | FGFR1 (0.57) | FGFR1THRBHPGDSIK1SIK2 | |
| SCHEMBL1761648 | 0.89 | FGFR1 (0.63) | FGFR1HPGDSIK1SIK2SIK3 | |
| SCHEMBL1762000 | 0.89 | GABRA1 (0.42) | FGFR1THRBHPGDSIK1SIK2 | |
| SCHEMBL1761996 | 0.85 | FGFR1 (0.44) | FGFR1THRBHPGDMAPK1CYP1A2 | |
| SCHEMBL1761991 | 0.85 | FGFR1 (0.55) | FGFR1THRBHPGDSIK1SIK2 | |
| SCHEMBL1761951 | 0.85 | FGFR1 (0.57) | FGFR1HPGDSIK1SIK2SIK3 | |
| SCHEMBL1761977 | 0.84 | FGFR1 (0.67) | FGFR1THRBHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1761581 | 0.83 | FGFR1 (0.55) | FGFR1HPGDSIK1SIK2SIK3 | |
| SCHEMBL1761776 | 0.83 | FGFR1 (0.55) | FGFR1THRBHPGDSIK1SIK2 | |
| SCHEMBL1761985 | 0.82 | FGFR1 (0.63) | FGFR1HPGDSIK1SIK2SIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | claimed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | claimed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | claimed |
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | claimed |
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-7902230-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-03-08 | — | — | US | disclosed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-2001855-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110374-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885THRB 404/4885HPGD 1966/4885 |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885THRB 404/4885HPGD 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.